XERIS PHARMACEUTICALS INC short interest in 2021
In 2021, XERIS PHARMACEUTICALS INC's disclosed short interest ran from 11.03% of shares outstanding on 15 Jan 2021 to 5.54% on 31 Dec 2021, a change of -5.49 percentage points. The year's high was 27.99% on 31 Mar 2021 and its low 4.57% on 30 Nov 2021, averaging 13.27% across 23 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 9.92 days on 30 Apr 2021. Full history: XERIS PHARMACEUTICALS INC.
Cite this page
2021 in figures
- Start of year
- 11.03% (15 Jan 2021)
- End of year
- 5.54% (31 Dec 2021)
- Change
- -5.49 pp
- High
- 27.99% (31 Mar 2021)
- Low
- 4.57% (30 Nov 2021)
- Average
- 13.27%
- Highest days to cover
- 9.92 (30 Apr 2021)
- SEC filings marked
- 6
Every report in 2021
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 15 Jan 2021 | 11.03% | 2.92 | |
| 29 Jan 2021 | 9.85% | 3.01 | |
| 12 Feb 2021 | 12.02% | 2.07 | |
| 26 Feb 2021 | 17.37% | 4.23 | |
| 15 Mar 2021 | 21.68% | 3.71 | 10-K filed, results (8-K) |
| 31 Mar 2021 | 27.99% | 4.31 | |
| 15 Apr 2021 | 27.68% | 9.03 | |
| 30 Apr 2021 | 20.12% | 9.92 | |
| 14 May 2021 | 23.01% | 6.93 | 10-Q filed, results (8-K) |
| 28 May 2021 | 23.04% | 8.12 | |
| 15 Jun 2021 | 23.46% | 2.50 | |
| 30 Jun 2021 | 20.20% | 3.42 | |
| 30 Jul 2021 | 8.11% | 4.11 | |
| 13 Aug 2021 | 6.70% | 1.36 | 10-Q filed, results (8-K) |
| 31 Aug 2021 | 7.36% | 1.00 | |
| 15 Sep 2021 | 6.46% | 3.99 | |
| 30 Sep 2021 | 6.13% | 4.36 | |
| 15 Oct 2021 | 5.08% | 2.05 | |
| 29 Oct 2021 | 5.78% | 1.62 | |
| 15 Nov 2021 | 6.62% | 2.08 | |
| 30 Nov 2021 | 4.57% | 1.38 | |
| 15 Dec 2021 | 5.30% | 2.46 | |
| 31 Dec 2021 | 5.54% | 1.00 |
See also: XERIS PHARMACEUTICALS INC's full history · most shorted US stocks of 2021 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.